Management of metallo-ß-lactamase-producing Enterobacterales infections: a modified Delphi study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carmeli Y.
- Price M.
- Daikos G.L.
- Falcone M.
- Gales A.C.
- Hagel S.
- Omrani A.S.
- Todi S.
- Wang M.
- Gheorghe M.
- Hauber B.
- Little C.J.
- Townsend A.
Grupos
Abstract
Background: and objectives Metallo-ß-lactamase (MBL)-producing Enterobacterales infections are an urgent global healthcare problem with limited treatment options. To obtain greater understanding of international perspectives on optimal management of serious infections due to MBL-producing Enterobacterales, we used a modified Delphi process to elicit experts’ opinion and establish consensus. Methods: A Delphi panel comprising 10 expert physicians experienced in antimicrobial-resistant bacterial infection management were surveyed on epidemiology, disease, testing and management of MBL-producing Enterobacterales infections. Consensus statements were based on survey responses and reviewed by the panel for endorsement or revisions to achieve consensus during a virtual meeting. Results: All panellists acknowledged MBL-producing Enterobacterales as a key source of antimicrobial resistance and infection in most countries. All agreed these infections have high morbidity and mortality, leading to the need for critical-level care, longer hospital stays and significant healthcare costs. The negative clinical and economic consequences of MBL-producing Enterobacterales are compounded by inappropriate use of multidrug antimicrobial regimens. Therefore, a specific MBL-targeting agent is considered desirable. When aztreonam-avibactam and cefiderocol are available, the preferred first-line treatment is aztreonam-avibactam, per in vitro data showing aztreonam-avibactam activity against >90% of New Delhi MBL-producing Enterobacterales. If aztreonam-avibactam or cefiderocol are unavailable, treatment options are limited to co-administration of antimicrobials. Regional differences made it difficult to achieve unanimous consensus across all survey questions due to differences in patient factors, local epidemiology and testing availability. Conclusions: The Delphi panel reached consensus on optimal management of MBL-producing Enterobacterales, confirming need for targeted MBL treatment, with monotherapy preferred where available. © The Author(s) 2026. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Datos de la publicación
- ISSN/ISSNe:
- 2632-1823, 2632-1823
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 41777798
- Enlace a otro recurso:
- www.scopus.com
JAC-Antimicrobial Resistance OXFORD UNIV PRESS
Citas Recibidas en Scopus: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- avibactam plus aztreonam; avibactam plus ceftazidime; aztreonam; beta lactam antibiotic; carbapenemase; cefiderocol; colistin; fosfomycin; metallo beta lactamase; New Delhi metallo beta lactamase; oxacillinase 48; tigecycline; unclassified drug; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; Article; Brazil; carbapenem resistant Klebsiella pneumoniae; carbapenemase producing Enterobacteriaceae; China; clinical decision making; consensus development; Delphi study; drug safety; Enterobacteriaceae infection; extended spectrum beta lactamase producing Enterobacteriaceae; first-line treatment; Germany; Gram negative infection; Greece; health care cost; health survey; hospitalization; human; in vitro study; India; infectious agent; infectious disease specialist; intensive care; internist; Israel; Italy; liver toxicity; microbiologist; monotherapy; morbidity; mortality; multidrug resistance; multidrug resistant bacterium; nephrotoxicity; physician; prescribing error; Qatar
Cita
Carmeli Y,Price M,Daikos GL,Falcone M,Gales AC,Hagel S,Omrani AS,RAMIREZ P,Todi S,Wang M,Gheorghe M,Hauber B,Little CJ,Townsend A. Management of metallo-ß-lactamase-producing Enterobacterales infections: a modified Delphi study. JAC-Antimicrob. Resist. 2026. 8. (1):dlag030. IF:3,900. (2).
Portal de investigación